Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus LUMI SPORYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus LUMI SPORYN.
BENSULFOID vs LUMI-SPORYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
LUMI-SPORYN is a synthetic antimicrobial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, leading to impaired cross-linking of peptidoglycan and osmotic lysis. It also exhibits concentration-dependent bactericidal activity.
Bensulfoid: not a recognized drug. No data available.
1000 mg IV every 8 hours over 1 hour for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
6-8 hours; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Renal 70-80% unchanged, biliary/fecal 20-30%
Category C
Category C
Topical Antibiotic
Topical Antibiotic